Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
NCT03919292 · Virginia Commonwealth University · PHASE1/PHASE2 · suspended · last registry update 2026-10-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Pending amendment approval” | – | Registry record, Virginia Commonwealth University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-27Phase 3 first posted: Jiangsu Aosaikang Pharmaceutical Co., Ltd., ASKC202 + ASKC202 placebo (NCT07897188)
- 2026-10-26Also stopped (terminated): Merus B.V., MCLA-129 + Osimertinib (NCT04868877)
- 2026-10-16Also stopped (withdrawn): West China Hospital, Lysogenic HSV virus. + Tislelizumab (NCT06741982)
- 2026-10-08Also stopped (terminated): Jin Hyoung Kang, Lazertinib + Pemetrexed (NCT05477615)
- 2026-10-05Also stopped (withdrawn): Biotech Pharmaceutical Co., Ltd., Nimotuzumab injection + Placebo (NCT06343116)
- 2026-09-21Also stopped (terminated): Massachusetts General Hospital, Niraparib + Osimertinib (NCT03891615)
- 2026-09-15Also stopped (withdrawn): Roswell Park Cancer Institute, Cemiplimab + Cetuximab Sarotalocan Sodium (NCT06943664)
- 2026-07-31Phase 3 first posted: National Taiwan University Hospital, Osimertinib (NCT07738172)
- 2026-07-22Also stopped (terminated): M.D. Anderson Cancer Center, Everolimus + Neratinib (NCT03065387)
- 2026-07-16Phase 3 first posted: Sun Yat-sen University, Toripalimab combined with Nimotuzumab + Nimotuzumab (NCT07706985)
- 2026-07-02Phase 3 first posted: Bristol-Myers Squibb, Iza-bren + Osimertinib (NCT07680790)
- 2026-06-17Phase 3 first posted: Peking University Cancer Hospital & Institute, Afatinib + Toripalimab + Dalpiciclib + Pyrotinib (NCT07653451)
- 2026-06-12Results posted on the registry: Spectrum Pharmaceuticals, Inc, Poziotinib (NCT03318939)
- 2026-06-12Also stopped (terminated): Spectrum Pharmaceuticals, Inc, Poziotinib (NCT03318939)
- 2026-06-11Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Osimertinib (NCT07640789)
- 2026-06-11Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Osimertinib (NCT07642024)
- 2026-06-05Results posted on the registry: AstraZeneca, Osimertinib + Cisplatin (NCT04351555)
- 2026-06-03Also stopped (terminated): Petrov, Andrey, Afatinib Dimaleat + inhalation of afatinib dimaleate (NCT06897735)
- 2026-04-28Results posted on the registry: OHSU Knight Cancer Institute, Abemaciclib + Exemestane (NCT06630325)
- 2026-04-28Also stopped (terminated): OHSU Knight Cancer Institute, Abemaciclib + Exemestane (NCT06630325)
- 2026-04-27Also stopped (terminated): Partner Therapeutics, Inc., Afatinib Oral Tablet + Enzalutamide Pill (NCT05588609)
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-04-17Phase 3 first posted: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Nimotuzumab + Nimotuzumab, Benmelstobart (NCT07535567)
- 2026-03-17Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Osimertinib (NCT02971501)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision